[Nonspecific immunoreactivity in women with dysplasia and cancer of the uterine cervix].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Tosner.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Leucocyte migration inhibition in the presence of tumour crude ovarian tissue antigen was demonstrated in 64.51% of ovarian cancer patients, in 58.18% of other gynaecological carcinoma patients and in 19.04% of healthy individuals. Patients with benign ovarian disease showed 12.5% leucocyte migration inhibition. No significant difference was seen between results obtained in the presence of ovarian carcinoma antigen and normal ovary antigen.